Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27465072 | 1.00 | CES1 (0.52) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL2241627 | 0.97 | CES1 (0.55) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL4631953 | 0.84 | CES1 (0.48) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL2313487 | 0.82 | CES1 (0.46) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL16795637 | 0.82 | CES1 (0.46) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL28102836 | 0.82 | CES1 (0.52) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL9364120 | 0.82 | CES1 (0.46) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL11645900 | 0.80 | TDP1 (0.46) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL12095508 | 0.80 | CES1 (0.55) | CES1CES2AKR1B1TSHRMEN1 | |
| SCHEMBL822099 | 0.80 | CES1 (0.55) | CES1CES2AKR1B1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4281076-A1 | PROCESSES FOR PURIFICATION OF BICTEGRAVIR INTERMEDIATES | Laurus Labs Limited (IN) | 2023-11-29 | — | — | EP | claimed |
| WO-2023288227-A1 | ENZYME-LOADED POLYMERIC NANOPARTICLES AND METHODS OF MANUFACTURE AND USE OF SAME | UNIVERSITY OF WASHINGTON (US) | 2023-01-19 | — | — | WO | claimed |
| US-20220071961-A1 | Dosing Regimen of Bicyclic Substituted Pyrazolone Azo Derivative | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-03-10 | — | — | US | claimed |
| EP-3909645-A1 | DOSING REGIMEN OF BICYCLIC SUBSTITUTED PYRAZOLONE AZO DERIVATIVE | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-11-17 | — | — | EP | claimed |
| US-20260102386-A1 | USE OF HEXOKINASE 2/MITOCHONDRIA-DETACHING COMPOUNDS FOR TREATING HEXOKINASE-2 (HK2)-EXPRESSING CANCERS | VIDAC PHARMA LTD. (IL) | 2026-04-16 | — | — | US | disclosed |
| US-12527782-B2 | Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (HK2)-expressing cancers | VIDAC PHARMA LTD. (IL) | 2026-01-20 | — | — | US | disclosed |
| US-12162868-B2 | Piperazine derivatives, pharmaceutical compositions and methods of use thereof | Vidac Pharma Ltd.. (IL) | 2024-12-10 | — | — | US | disclosed |
| EP-4464334-A2 | USE OF COMPOUNDS FOR TREATING HK2-EXPRESSING CANCERS | VIDAC Pharma Ltd. (IL) | 2024-11-20 | — | — | EP | disclosed |
| US-12083111-B2 | Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses | Vidac Pharma Ltd .. (IL) | 2024-09-10 | — | — | US | disclosed |
| WO-2023224303-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME, AND MEDICAL USE THEREOF | 재단법인 한국파스퇴르연구소 | 2023-11-23 | — | — | WO | disclosed |
| WO-2023288227-A1 | ENZYME-LOADED POLYMERIC NANOPARTICLES AND METHODS OF MANUFACTURE AND USE OF SAME | UNIVERSITY OF WASHINGTON (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20220160812-A1 | A PHARMACEUTICALLY ACTIVE SUBSTANCE | CYTOGENESIS LTD. (GB) | 2022-05-26 | — | — | US | disclosed |
| US-4107431-A | ANTIBIOTICS | GLAXO LABORATORIES LIMITED (GB) | 1978-08-15 | — | — | US | disclosed |
| US-4086362-A | Prostenoic acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1978-04-25 | — | — | US | disclosed |
| US-4060687-A | Cephalosporins having a 3-α substituted alkyl grouping | MERCK & CO., INC. (US) | 1977-11-29 | — | — | US | disclosed |
| US-4032521-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1977-06-28 | — | — | US | disclosed |
| US-4007174-A | Cephalosporin compounds | GLAXO LABORATORIES LIMITED (EN) | 1977-02-08 | — | — | US | disclosed |
| US-3962224-A | CHEMICAL INTERMEDIATES FOR ANTIBIOTICS | MERCK & CO., INC. (US) | 1976-06-08 | — | — | US | disclosed |
| US-3947413-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1976-03-30 | — | — | US | disclosed |
| US-3936443-A | Penicillin antibiotics | GLAXO LABORATORIES LIMITED (EN) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220071961-A1 | Dosing Regimen of Bicyclic Substituted Pyrazolone Azo Derivative | CYP3A5, CYP11B2, CYP3A43 | CES1 1051/4885CES2 1984/4885AKR1B1 94/4885 |
| US-12083111-B2 | Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses | HK2, AK2, HK1 | CES1 3245/4885CES2 2492/4885AKR1B1 2432/4885 |
| US-12527782-B2 | Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (HK2)-expressing cancers | HK2, HK1, AK2 | CES1 1380/4885CES2 3334/4885AKR1B1 1176/4885 |
| US-20260102386-A1 | USE OF HEXOKINASE 2/MITOCHONDRIA-DETACHING COMPOUNDS FOR TREATING HEXOKINASE-2 (HK2)-EXPRESSING CANCERS | HK2, HK1, AK2 | CES1 2149/4885CES2 1383/4885AKR1B1 1502/4885 |
| US-12162868-B2 | Piperazine derivatives, pharmaceutical compositions and methods of use thereof | CCND2, HRAS, PAK5 | CES1 4358/4885CES2 4233/4885AKR1B1 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.